Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog
Jeffrey Paul, PhD

Jeffrey Paul, PhD

Principal at JPharm Consulting

Connect with Jeffrey Paul, PhD on LinkedIn

About the author: Dr. Paul is a clinical pharmacology consultant to the pharmaceutical industry, focusing his practice on early clinical development of drugs for CNS and pain. Dr. Paul has spent nearly 30 years in pharmaceutical R&D, including Discovery, and Phase 1 through 4 clinical development phases. He has global clinical and regulatory experience, especially in Europe and Japan. He has worked at Berlex, Pfizer (formally Wyeth), and Astellas at the Executive Director/Assistant VP level. Dr. Paul has an adjunct faculty appointment at Drexel Medical College (Philadelphia) where he teaches in the graduate Drug Discovery and Development program and Neuropharmacology courses; and is active in Drexel’s Clinical Research for Health Professionals Program and Clinical & Translational Research Institute. Dr. Paul is also active in promoting translation medicine as a member of the Executive Committee of Translation, Clinical Pharmacology Division of American Society for Pharmacology & Experimental Therapeutics (ASPET).

Posts by Jeffrey Paul, PhD

Organ-on-Chip: Efficient Translational Platform

Posted on December 12th, 2016 in Pharma R&D

Several years ago, cellular and subcellular platforms aimed to replace in vivo animal testing. Cellular and molecular scientists, armed with their pipettes, shouted the battle hymn of the translational scientist: “From bench to bedside.” (more…)

Can your Microbiome Make you Fat?

Posted on November 9th, 2016 in Pharma R&D

This is a story about fecal microbiota transplant (FMT): FMT is a procedure in which fecal matter is collected from a healthy donor and placed in a recipient, typically by colonoscopy. The purpose? (more…)

Immune Checkpoints: New Promises in Cancer Treatment

Posted on October 26th, 2016 in Pharma R&D

Cancer immunotherapy (especially checkpoint inhibitors) is hot in the cancer therapeutics world, but we are still learning about how best to use them and in which patients. The current explosion in new cancer immunotherapies relates to braking T-cell activation: checkpoint therapies. (more…)

Venturing into the Microbiome

Posted on September 28th, 2016 in Pharma R&D

The growing library of bacterial genomic material and microorganisms that reside within the human host is termed the microbiome. Microbiota, a less-used term, refers to the community of single cell organisms (i.e. bacteria, fungi, virus, etc.) that inhabit us, the superhost human organism. Prior to genomic sequencing, bacterial identification occurred by laboratory isolation and culturing. (more…)

  1. 1
  2. 2
  3. 3